Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension

Thorax

Volumn 73, Issue 6, 2018, Pages 581-583

  Richeldi, Luca ^a   Kreuter, Michael ^b   Selman, Moisés ^c   Crestani, Bruno ^d   Kirsten, Anne Marie ^e   Wuyts, Wim A ^f   Xu, Zuojun ^g   Bernois, Katell ^h   Stowasser, Susanne ⁱ   Quaresma, Manuel ^b,i   Costabel, Ulrich ^j  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

^d BICHAT HOSPITAL   (France)

^e GERMAN CENTER FOR LUNG RESEARCH   (Germany)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^g PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^h BOEHRINGER INGELHEIM   (France)

ⁱ BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^j RUHRLANDKLINIK   (Germany)

more..

Author keywords

Idiopathic pulmonary fibrosis

Indexed keywords

NINTEDANIB; PLACEBO; ENZYME INHIBITOR; INDOLE DERIVATIVE;

ABDOMINAL PAIN; ARTICLE; BODY WEIGHT LOSS; BRONCHITIS; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DESCRIPTIVE RESEARCH; DIARRHEA; DISEASE COURSE; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FIBROSING ALVEOLITIS; HUMAN; MAJOR CLINICAL STUDY; NAUSEA; OPEN STUDY; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; RHINOPHARYNGITIS; SIDE EFFECT; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VOMITING; AGED; FEMALE; MALE; MIDDLE AGED; SURVIVAL RATE;

AGED; ENZYME INHIBITORS; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INDOLES; MALE; MIDDLE AGED; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 85050991633     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2016-209701     Document Type: Article

References (8)

1. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183:788-824
2. Ley B, Collard HR, King TE. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011;183:431-40
3. Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011;365:1079-87
4. Richeldi L. Du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014;370:2071-82
5. Boehringer Ingelheim Pharmaceuticals, Inc. OFEV™ (nintedanib) prescribing information. 2016. http://bidocs. boehringer-ingelheim. com/BIWebAccess/ViewServlet. ser?. docBase= renetnt& folderPath=/Prescribing+ Information/PIs/Ofev/ofev.pdf (accessed 21 Apr 2016)
6. Boehringer Ingelheim. Ofev (nintedanib) summary of product characteristics. 2016. http://www.ema. europa. eu/ema/index. jsp?. curl= pages/medicines/human/medicines/003821/human-med-001834. jsp& mid= WC0b01ac058001d124 (accessed 21 Apr 2016)
7. Richeldi L, Cottin V, du Bois RM, et al. Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS® trials. Respir Med 2016;113:74-9
8. Crestani B, Quaresma M, Kaye M, et al. Longterm treatment with nintedanib in patients with IPF: an update from INPULSIS®-ON. Eur Respir J 2016;48(Suppl 60):OA4960.